GlassScriptPhysician profile
Christopher J Charbonnet
NPI 1225049968
$10,462.16
in general payments reported to CMS, 2019-2025
27 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,376 · 2020: $555 · 2021: $749 · 2022: $2,562 · 2023: $1,508 · 2024: $1,648 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,220.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,710.05 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, Intracept |
| Vertiflex, INC. | $1,792.62 | 2019 | |
| Spinal Simplicity, LLC | $1,563.21 | 2022-2025 | Ha Minuteman G3-R |
| Medtronic, INC. | $1,094.03 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Electronic Waveform Lab, INC. | $592.02 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $552.20 | 2019-2025 | Belbuca |
| Saluda Medical Americas, INC. | $331.50 | 2024-2025 | Evoke |
| Painteq LLC | $329.66 | 2022-2024 | Painteq |
| Scilex Pharmaceuticals INC. | $258.83 | 2019-2023 | Ztlido |
| Nevro Corp. | $200.80 | 2019-2024 | Senza |
| Globus Medical, INC. | $143.52 | 2025 | Vyrsa V1, Senza |
| Abbott Laboratories | $127.03 | 2019-2023 | Proclaim |
| Averitas Pharma INC. | $123.28 | 2023-2025 | Qutenza |
| Pfizer INC. | $109.82 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $105.18 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $73.74 | 2025 | Sprint Pns System |
| Relievant Medsystems, INC. | $47.69 | 2022 | |
| Hikma Pharmaceuticals USA | $45.73 | 2021-2022 | |
| Redhill Biopharma INC. | $44.69 | 2020-2021 | |
| Horizon Therapeutics Plc | $41.99 | 2021-2022 | |
| Protega Pharmaceutials INC | $34.20 | 2025 | Roxybond |
| Avanos Medical | $33.27 | 2023 | Generator |
| Forte Bio-Pharma LLC | $28.54 | 2024 | Prolate, Nalocet |
| Virtus Pharmaceuticals LLC | $24.37 | 2025 | Levorphanol Tartrate |
| Nalu Medical, INC. | $22.88 | 2024 | Nalu Neurostimulation System |
| Stimwave Technologies Incorporated | $16.80 | 2021 | |
| Amgen INC. | $14.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Charbonnet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.